News Pfizer’s Lyrica fails phase 3 trial in epilepsy Pfizer’s Lyrica has failed to meet its primary endpoint in a phase 3 trial in primary generalised tonic-clonic (PGTC) seizures.
News Acquisitive Lilly offers $2.88bn for Merida Bio Lilly has continued its lengthy streak of acquisitions in 2026 with a $2.88 billion agreement to buy immunology and inflammation specialist Merida.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
